Hot Features
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-con... Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02 | -1.32450331126 | 1.51 | 1.55 | 1.48 | 23683 | 1.49824948 | CS |
| 4 | -0.31 | -17.2222222222 | 1.8 | 1.83 | 1.43 | 42183 | 1.57053414 | CS |
| 12 | -0.44 | -22.7979274611 | 1.93 | 2.33 | 1.43 | 92358 | 1.88669763 | CS |
| 26 | 0.1 | 7.19424460432 | 1.39 | 2.33 | 1.23 | 98066 | 1.64486448 | CS |
| 52 | -0.28 | -15.8192090395 | 1.77 | 2.33 | 1.23 | 119573 | 1.6147035 | CS |
| 156 | 0.39 | 35.4545454545 | 1.1 | 4.26 | 0.91 | 107219 | 1.98061495 | CS |
| 260 | -1.59 | -51.6233766234 | 3.08 | 6.19 | 0.61 | 135358 | 2.2785873 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.